SEC Form 4 · accession 0001237899-18-000024
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Yancopoulos
Officer — President and Chief Scientific · Director
Period of report
Dec 13, 2018
Accepted (ET)
Dec 17, 2018 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2018 | M | 150,000 | $16.80 | A | 150,000 | D | |
| Common Stock | Dec 13, 2018 | F | 76,863 | $377.31 | D | 73,137 | D | |
| Common Stock | Dec 13, 2018 | M | 94,048 | $16.80 | A | 167,185 | D | |
| Common Stock | Dec 13, 2018 | F | 48,192 | $377.31 | D | 118,993 | D | |
| Common Stock | Dec 13, 2018 | G | 118,993 | $0.00 | D | 0 | D | |
| Common Stock | Dec 13, 2018 | G | 118,993 | $0.00 | A | 602,594 | I | by Trust |
| Common Stock | holding | — | — | — | 5,728 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 75,036 | I | by 2017 GRAT | |
| Common Stock | holding | — | — | — | 400,000 | I | by 2018 GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $16.80 | Dec 13, 2018 | M | 150,000 | D | — | Dec 17, 2018 | Common Stock | 150,000 | 94,048 | D |
| Non-Qualified Stock Option (right to buy)F2 | $16.80 | Dec 13, 2018 | M | 94,048 | D | — | Dec 17, 2018 | Common Stock | 94,048 | 0 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2With respect to 150,000 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 94,048 underlying shares, the stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant.